RET and hematocrit: Previous studies have shown that HT shares with papillary cancer some molecular profiles such as, for example, the re-arrangement of RET proto-oncogene (RET/PTC oncogene) [11], BRAF mutation [12], and phosphatidylinositol 3-kinase (PI3k) pathway activation [13,14].